PMID- 27522583 OWN - NLM STAT- MEDLINE DCOM- 20170803 LR - 20240426 IS - 1432-0851 (Electronic) IS - 0340-7004 (Print) IS - 0340-7004 (Linking) VI - 65 IP - 10 DP - 2016 Oct TI - Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy. PG - 1213-22 LID - 10.1007/s00262-016-1883-9 [doi] AB - Loss of tumor cell human leukocyte antigen (HLA) is an immune escape mechanism for malignancies. However, the effect of low HLA class I or class II expression in diffuse large B cell lymphoma (DLBCL) treated with chemoimmunotherapy with the monoclonal antibody rituximab is largely unknown. We retrospectively analyzed samples and other data from 144 patients with DLBCL who were newly diagnosed in our institution and treated with standard R-CHOP therapy. We used antibodies against pan-HLA class I and pan-HLA class II molecules to assess HLA expression and its effect on prognosis. In a multivariate analysis, loss of HLA class II expression was a significantly independent adverse factor for progression-free survival (PFS; hazard ratio 2.3; 95 % confidence interval 1.2-4.6; P = 0.01). Although HLA class I loss of expression did not correlate with prognosis, the combination of HLA class I(+) with either low peripheral lymphocyte count or CD3(+) lymphocyte count was an adverse prognostic factor for PFS. Loss of HLA class II is an International Prognostic Index (IPI)-independent adverse factor for PFS in patients with DLBCL treated with standard therapy. However, in contrast to other solid cancers, HLA class I loss was not solely a prognostic factor in DLBCL. FAU - Tada, Kohei AU - Tada K AD - Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. AD - Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan. AD - Immunotherapy and Cell Therapy Service, St. Luke's International Hospital, Tokyo, Japan. FAU - Maeshima, Akiko Miyagi AU - Maeshima AM AD - Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan. FAU - Hiraoka, Nobuyoshi AU - Hiraoka N AD - Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan. FAU - Yamauchi, Nobuhiko AU - Yamauchi N AD - Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Maruyama, Dai AU - Maruyama D AD - Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Kim, Sung-Won AU - Kim SW AD - Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Watanabe, Takashi AU - Watanabe T AD - Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. AD - Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan. FAU - Katayama, Naoyuki AU - Katayama N AD - Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan. FAU - Heike, Yuji AU - Heike Y AD - Immunotherapy and Cell Therapy Service, St. Luke's International Hospital, Tokyo, Japan. AD - Immunotherapy Research Field, Translational Research Group, and Translational Medicine Department, Phase 1 Group, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan. FAU - Tobinai, Kensei AU - Tobinai K AD - Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Kobayashi, Yukio AU - Kobayashi Y AUID- ORCID: 0000-0003-2378-7865 AD - Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. ykkobaya@ncc.go.jp. LA - eng PT - Journal Article DEP - 20160813 PL - Germany TA - Cancer Immunol Immunother JT - Cancer immunology, immunotherapy : CII JID - 8605732 RN - 0 (Antibodies, Monoclonal, Murine-Derived) RN - 0 (HLA Antigens) RN - 0 (Histocompatibility Antigens Class I) RN - 0 (Histocompatibility Antigens Class II) RN - 0 (R-CHOP protocol) RN - 4F4X42SYQ6 (Rituximab) RN - 5J49Q6B70F (Vincristine) RN - 80168379AG (Doxorubicin) RN - 8N3DW7272P (Cyclophosphamide) RN - VB0R961HZT (Prednisone) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antibodies, Monoclonal, Murine-Derived MH - Antineoplastic Combined Chemotherapy Protocols MH - Cyclophosphamide MH - Doxorubicin MH - Female MH - Follow-Up Studies MH - HLA Antigens/*metabolism MH - Histocompatibility Antigens Class I/*metabolism MH - Histocompatibility Antigens Class II/*metabolism MH - Humans MH - Immunohistochemistry/*methods MH - Lymphoma, Large B-Cell, Diffuse/*diagnosis/drug therapy/mortality MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Predictive Value of Tests MH - Prednisone MH - Prognosis MH - Rituximab MH - Survival Analysis MH - Tumor Escape MH - Vincristine MH - Young Adult PMC - PMC11029644 OTO - NOTNLM OT - Absolute lymphocyte count OT - CD3 count OT - Human leukocyte antigen (HLA) OT - Prognosis OT - Rituximab (RTX) COIS- The authors have no conflicts of interest to declare. This research was approved by the Institutional Review Board of the National Cancer Center (2014-185). EDAT- 2016/08/16 06:00 MHDA- 2017/08/05 06:00 PMCR- 2016/08/13 CRDT- 2016/08/15 06:00 PHST- 2015/09/25 00:00 [received] PHST- 2016/08/06 00:00 [accepted] PHST- 2016/08/15 06:00 [entrez] PHST- 2016/08/16 06:00 [pubmed] PHST- 2017/08/05 06:00 [medline] PHST- 2016/08/13 00:00 [pmc-release] AID - 10.1007/s00262-016-1883-9 [pii] AID - 1883 [pii] AID - 10.1007/s00262-016-1883-9 [doi] PST - ppublish SO - Cancer Immunol Immunother. 2016 Oct;65(10):1213-22. doi: 10.1007/s00262-016-1883-9. Epub 2016 Aug 13.